A photo of Sonata Jodele.

Member, Division of Bone Marrow Transplantation and Immune Deficiency

Professor, UC Department of Pediatrics



Board Certified

My Biography & Research


I am an internationally recognized expert in every aspect of transplant-associated thrombotic microangiopathy (TMA), working on both clinical and research applications. My work was instrumental in linking TMA pathophysiology to the complement pathway, which demonstrated the relationship of the disease to specific clinical and genetic factors. Then, I established a new paradigm for therapy with inhibition of the complement pathway.

My ongoing research aims to develop new and better therapies for TMA. Currently, I lead multi-disciplinary international collaborative groups and research projects with clinicians and scientists from Germany, Switzerland, Italy and Japan. I also serve as a clinical consultant for physicians throughout the world regarding care of complex patients with TMA.

In previous work, I led the first prospective TMA biomarker and genetic predisposition studies. My efforts resulted in practical applications for clinical care, as well as comprehensive diagnostic laboratory panels now offered for patients worldwide. I also proposed new diagnostic algorithms and risk stratification data for TMA to help guide timely therapy initiation.

Additionally, I piloted ground-breaking complement blocking therapeutic agents for hematopoietic stem cell transplantation (HSCT) recipients living with severe TMA while also describing unique drug pharmacokinetics in this patient population. As a result of this work, the first prospective early intervention clinical study opened at four major United States pediatric healthcare centers. The study evaluates eculizumab for stem cell transplant recipients with high risk TMA.

My continuing research is supported by the National Institutes of Health (NIH) as well as institutional and industry-sponsored grants.

Clinical Interests

Bone marrow transplantation and cellular therapies

Research Interests

Thrombotic microangiopathies; organ toxicity prevention in transplant patients

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Bone Marrow Transplantation BMT, Cancer and Blood Diseases

Research Divisions

Bone Marrow Transplantation and Immune Deficiency

My Education

MD: Vilnius University School of Medicine, Vilnius, Lithuania, 1988-1994.

Residency: Pediatrics, SUNY Health Science Center at Brooklyn, Brooklyn, NY, 1998-2001.

Fellowship: Pediatric Hematology/Oncology, Children's Hospital Los Angeles and Saban Research Institute, Keck School of Medicine University of Southern California, Los Angeles, CA, 2001-2004.

Certifications: Pediatrics, 2001; Pediatric Hematology / Oncology, 2004.

Licenses: California, 2001-present; Ohio, 2004-present.

My Publications

Selected Publication

Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Jodele, S; Dandoy, CE; Lane, A; Laskin, BL; Laskin, B; Teusink-Cross, A; Myers, KC; Wallace, G; Nelson, AS; Nelson, A; et al. Blood. 2020; 135:1049-1057.

Interferon-complement loop in transplant-associated thrombotic microangiopathy. Jodele, S; Medvedovic, M; Luebbering, N; Chen, J; Dandoy, CE; Laskin, BL; Davies, SM. Blood Advances. 2020; 4:1166-1177.

High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. Jodele, S; Dandoy, CE; Myers, K; Wallace, G; Lane, A; Teusink-Cross, A; Weiss, B; Davies, SM. Bone Marrow Transplantation. 2018; 53:1311-1318.

Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination. Jodele, S; Dandoy, CE; Danziger-Isakov, L; Myers, KC; El-Bietar, J; Nelson, A; Wallace, G; Teusink-Cross, A; Davies, SM. Biology of Blood and Marrow Transplantation. 2016; 22:1337-1340.

New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Jodele, S; Dandoy, CE; Myers, KC; El-Bietar, J; Nelson, A; Wallace, G; Laskin, BL. Transfusion and Apheresis Science. 2016; 54:181-190.

Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Jodele, S; Fukuda, T; Mizuno, K; Vinks, AA; Laskin, BL; Goebel, J; Dixon, BP; Chima, RS; Hirsch, R; Teusink, A; et al. Biology of Blood and Marrow Transplantation. 2016; 22:307-315.

Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Jodele, S; Davies, SM; Lane, A; Khoury, J; Dandoy, C; Goebel, J; Myers, K; Grimley, M; Bleesing, J; El-Bietar, J; et al. Blood. 2014; 124:645-653.

Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Jodele, S; Fukuda, T; Vinks, A; Mizuno, K; Laskin, BL; Goebel, J; Dixon, BP; Teusink, A; Pluthero, FG; Lu, L; et al. Biology of Blood and Marrow Transplantation. 2014; 20:518-525.

Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Jodele, S; Licht, C; Goebel, J; Dixon, BP; Zhang, K; Sivakumaran, TA; Davies, SM; Pluthero, FG; Lu, L; Laskin, BL. Blood. 2013; 122:2003-2007.

Prospective pilot trial of calcipotriene as a novel topical treatment for acute skin graft versus host disease. Wallace, G; Khandelwal, P; Myers, KC; Perentesis, EM R; Lane, A; Teusink-Cross, A; Smiley, K; Davies, SM; Jodele, S. Bone Marrow Transplantation. 2021; 56:1441-1444.